The need for routine bleomycin test dosing in the 21st century

Annals of Pharmacotherapy

Volumn 39, Issue 11, 2005, Pages 1897-1902

  Lam, Masha S H ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Anaphylactic reactions; Hypersensitivity; bleomycin test dose

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BICARBONATE; BLEOMYCIN; DIAZEPAM; DIPHENHYDRAMINE; HEPARIN; HYDROCORTISONE; HYPERTENSIVE FACTOR; METHYLPREDNISOLONE; PARACETAMOL; PROMETHAZINE; PYROGEN;

ANAPHYLAXIS; ANAPLASTIC CARCINOMA; ANURIA; ASSISTED VENTILATION; BLOOD TRANSFUSION; CHILL; DEATH; DELIRIUM; DESENSITIZATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE CALCULATION; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEVER; FLUID THERAPY; HISTIOCYTIC LYMPHOMA; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INJECTION SITE REACTION; INTERNET; KIDNEY FAILURE; LUNG CARCINOMA; LUNG INFILTRATE; LUNG LAVAGE; LYMPHOCYTOMA; LYMPHOMA; MEDLINE; METABOLIC ACIDOSIS; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NAUSEA; OVARY TERATOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; RESPIRATORY ARREST; REVIEW; SARCOMA; SHOCK; SOLID TUMOR; STEROID THERAPY; STEVENS JOHNSON SYNDROME; STREPTOMYCES; STREPTOMYCES VERTICILLUS; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; TACHYPNEA; TEST DOSE; TONIC CLONIC SEIZURE; TOTAL PARENTERAL NUTRITION; UNCONSCIOUSNESS; UTERINE CERVIX CARCINOMA; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; DRUG MONITORING; FORECASTING; HUMANS;

EID: 27344459345     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G235     Document Type: Review

References (24)

1. Sonntag RW. Bleomycin (NSC-125066): Phase I clinical study. Cancer Chemother Rep 1972;56:197-205.
2. Package insert. Blenoxane (bleomycin). http://home.intekom.com/pharm/ bm_squib/blenoxan.html (accessed 2005 Apr 3).
3. Blum RH, Carter SK, Agre KA. A clinical review of bleomycin-a new antineoplastic agent. Cancer 1973;31:903-14.
4. Durkin WJ, Pugh RP, Solomon J, Rosen P, Pajak TF, Bateman JR. Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology 1976;33:140-5.
5. Schulmeister L. Developing guidelines for bleomycin test dosing. Oncol Nurs Forum 1989;16:205-7.
6. Skeel RT. Antineoplastic drugs and biological response modifiers: classification, use, and toxicity of clinically useful agents. In: Handbook of cancer chemotherapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 1999:63-143.
7. Rosenfelt F, Palmer J, Weinstein I, Rosenbloom B. A fatal hyperpyrexial response to bleomycin following prior therapy: a case report and literature review. Yale J Biol Med 1982;55:529-31.
8. Ma DD, Isbister JP. Cytotoxic-induced fulminant hyperpyrexia. Cancer 1980;45:2249-51.
9. Leung WH, Lau JY, Chan TK, Kumana CR. Fulminant hyperpyrexia induced by bleomycin. Postgrad Med J 1989;65:417-9.
10. Carter JJ, McLaughlin ML, Bern MM. Bleomycin-induced fatal hyperpyrexia. Am J Med 1983;74:523-5.
11. Hoogstraten B, Haas CD, Haut A, Talley RW, Rivkin S, Isaacs BL. CCNU and bleomycin in the treatment of cancer: a Southwest Oncology Group Study. Med Pediatr Oncol 1975;1:95-106.
12. Inbar MJ, Baratz M, Figer A, Schpitzer-Reter E, Chaitchik S. Idiosyncratic reaction to bleomycin in an epithelial tumor. Cancer Chemother Pharmacol 1984;13:71-2.
13. Levy RL, Chiarillo S. Hyperpyrexia, allergic-type response and death occurring with low-dose bleomycin administration. Oncology 1980;37:316-7.
14. Khansur T, Little D, Tavassoli M. Fulminant and fatal angioedema caused by bleomycin treatment. Arch Intern Med 1984;144:2267.
15. Giaccone G, Risio M, Bonardi G, Calciati A. Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report. Tumori 1986;72:331-3.
16. Brodsky A, Aparici I, Argeri C, Goldenberg D. Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergistic bleomycin-cisplatin toxicity. J Clin Pharmacol 1989;29:821-3.
17. British Columbia Cancer Agency homepage. www.bccancer.bc.ca/HPI/ ChemotherapyProtocols/default.htm (accessed 2005 Jun 20).
18. Children's Oncology Group homepage. www.childrensoncologygroup.org (accessed 2005 Jun 20).
19. Eastern Cooperative Oncology Group homepage. http://ecog.dfci.harvard.edu (accessed 2005 Jun 20).
20. Haas CD, Coltman CA, Gottlieb JA, Haut A, Luce JK, Talley RW, et al. Phase II evaluation of bleomycin. A Southwest Oncology Group Study. Cancer 1976;28:8-12.
21. Dinarello CA, Ward SB, Wolff SM. Pyrogenic properties of bleomycin (NSC-125006). Cancer Chemother Rep 1973;57:393-8.
22. Geuenich S, Haberl C, Egger D, Kaspers U, Hultner L, Wilmanns W. Induction of leukotriene production by bleomycin and asparaginase in mast cells in vitro and in patients in vivo. Biochem Pharmacol 1998;55:447-53.
23. FDA MedWatch homepage. www.fda.gov/medwatch (accessed 2005 Jun 19).
24. Sampson HA, Muñoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005;115:584-91.